Attralus Therapeutic AT-02 Receives Orphan Drug Designation from the U.S. FDA for the Treatment of ATTR Amyloidosis
12 nov. 2024 07h00 HE
|
Attralus, Inc
NAPLES, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines and diagnostics to improve the lives of patients with...
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
07 août 2024 07h50 HE
|
ZyVersa Therapeutics
Extracellular ASC has a crucial role in aggregation and deposition of amyloid A fibrils leading to associated chronic inflammatory conditions.
Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)
30 mai 2024 07h00 HE
|
Attralus, Inc
AT-02, the company’s lead pan-amyloid removal therapeutic candidate, is currently being evaluated in a Phase 1 three-part trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis...
Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)
07 nov. 2023 07h00 HE
|
Attralus, Inc
124I-evuzamitide shown to be highly accurate for detection of cardiac amyloid across two independent investigator-initiated studies.124I-evuzamitide detects multiple types of systemic...
Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology
02 oct. 2023 07h00 HE
|
Attralus, Inc
Attralus announced eight data presentations related to the use of 124I-evuzamitide (AT-01), the company's pan-amyloid binding imaging agent, at ASNC 2023.
AL Amyloidosis Therapeutics Market is projected to rise at a 7.3% CAGR until 2033, being valued at US$ 4.56 billion | Future Market Insights, Inc.
20 mars 2023 06h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 20, 2023 (GLOBE NEWSWIRE) -- The global AL amyloidosis therapeutics market is expected to be worth US$ 2.25 billion by the year of 2023. The market, which is estimated to be worth...
Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate
17 oct. 2022 07h00 HE
|
Attralus, Inc
SAN FRANCISCO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic...
Attralus Announces New Clinical Data in ATTR CM and AL With AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent
12 sept. 2022 07h00 HE
|
Attralus, Inc
AT-01 shows increased LV uptake and LV amyloid activity in all cardiac ATTR and AL subjects, but in none of the controls (100% accuracy)AT-01 demonstrates significantly higher left ventricular uptake...
Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis
08 sept. 2022 07h00 HE
|
Attralus, Inc
AT-01 is a first-in-class pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosis in multiple organsSensitivity in those with previously diagnosed cardiac disease was 100%...
Attralus Presents Preclinical Data Demonstrating Potent Binding to All Types of Systemic and Cerebral Amyloid by its Pan-Amyloid Removal Candidate AT-04 at 18th International Symposium on Amyloidosis
07 sept. 2022 07h00 HE
|
Attralus, Inc
AT-04 demonstrates potent binding and promotes phagocytosis in ATTR and AL amyloidosisAT-04 binds potently to Aβ, tau, and α-synuclein, common amyloid pathologies in CNS disorders such as Alzheimer's ...